Introduction
GLP-1 receptor agonists have dominated recent clinical headlines, but another category of therapies has quietly gained attention across wellness clinics, sports medicine, and recovery-focused practices: peptide therapies.
Compounds such as BPC-157, TB-500, CJC-1295, and ipamorelin are increasingly being promoted for wound healing, muscle recovery, tissue repair, and overall recovery enhancement. As awareness grows, questions are emerging about the role these products may play in healthcare and whether they should be considered within managed care and workers' compensation programs.
While some peptides have shown encouraging results in preclinical research, many remain investigational, and questions surrounding clinical evidence, regulation, and reimbursement continue to evolve. Understanding the distinction between scientific promise and established evidence is essential. [1,2]
—
What Are Peptides?
Peptides are short chains of amino acids that act as signaling molecules throughout the body. They interact with specific cellular receptors involved in functions such as:
Growth
Inflammation
Tissue repair
Hormone regulation
Cellular communication
Their targeted activity has generated interest in a variety of therapeutic areas, particularly those involving injury recovery and regenerative medicine. [1,6]
Unlike many traditional medications, most of the recovery-focused peptides currently discussed in clinical and wellness settings are not FDA-approved for wound healing, tendon repair, or musculoskeletal recovery. Many are obtained through compounding pharmacies rather than conventional drug distribution channels. [2]
Peptides Generating Interest Today
BPC-157
BPC-157 is often promoted for:
Tendon healing
Ligament repair
Wound healing
Gastrointestinal recovery
Interest stems primarily from animal and laboratory studies demonstrating potential effects on angiogenesis and tissue repair. However, high-quality human clinical trials remain lacking, and no FDA-approved indication currently exists. [3]
TB-500
TB-500 is a synthetic version of thymosin beta-4, a naturally occurring protein involved in cellular migration and tissue repair.
It is frequently marketed for:
Muscle recovery
Soft tissue healing
Inflammation management
While some early studies have explored potential therapeutic applications, human evidence remains limited and TB-500 currently has no FDA-approved indication. [5]
GHK-Cu
GHK-Cu is a copper-binding peptide that has attracted attention because of its potential role in:
Collagen production
Skin repair
Wound healing
Cosmetic applications
Most available evidence remains limited to laboratory and animal studies, although the peptide continues to generate interest within regenerative medicine and aesthetic medicine communities. [6]
CJC-1295
CJC-1295 is a growth hormone-releasing hormone (GHRH) analogue designed to stimulate growth hormone and insulin-like growth factor-1 (IGF-1) production.
It is frequently marketed for:
Recovery
Muscle growth
Body composition
Anti-aging
However, it does not have any FDA-approved indication. In April 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted against continued compounding eligibility for CJC-1295. [2,4]
Ipamorelin
Ipamorelin is a growth hormone secretagogue that stimulates growth hormone release while attempting to minimize effects on other hormonal pathways.
It is often promoted for:
Recovery
Sleep
Body composition
Healthy aging
Like CJC-1295, widespread use has largely occurred outside of approved therapeutic indications, and compounding access became more restricted following PCAC review in 2026. [2,4]
The Regulatory Landscape Is Evolving
One of the most important developments affecting peptide therapies is the changing regulatory environment.
In April 2026, the FDA Pharmacy Compounding Advisory Committee (PCAC) reviewed several peptides commonly used in wellness and recovery settings. The committee voted against continued compounding access for both CJC-1295 and ipamorelin, while BPC-157 remained under active review. [2,4]
These developments have practical implications for healthcare organizations, payers, and workers' compensation programs. As regulatory requirements continue to evolve, questions surrounding product quality, compounding eligibility, and reimbursement may become increasingly important.
Key Takeaways
1. Peptide therapies are generating growing interest in recovery and regenerative medicine.
Compounds such as BPC-157, TB-500, CJC-1295, and ipamorelin are increasingly being promoted for healing, recovery, and tissue repair. [1,6]
2. Clinical evidence remains limited for many commonly marketed peptides.
While some have demonstrated encouraging findings in preclinical studies, few have substantial human clinical data supporting routine use. [3,5,6]
3. Regulation and reimbursement continue to evolve.
Recent FDA advisory committee decisions highlight the ongoing scrutiny surrounding peptide compounding and may influence future access, utilization, and coverage decisions. [2,4]
By: Mustafa Elhefnawi
PharmD Candidate (P3)
For questions, e-mail pharmd@prodigyrx.com
Citations
1. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today. 2015;20(1):122-128. https://www.sciencedirect.com/science/article/pii/S1359644614003997
2. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Updated 2025. Accessed October 2026. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
3. Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing. J Appl Physiol. 2011;110(3):774-780. https://journals.physiology.org/doi/full/10.1152/japplphysiol.00945.2010
4. Pharmacy Compounding Advisory Committee. Meeting Proceedings and Voting Records. U.S. Food and Drug Administration. April 2026. Accessed October 2026. https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee
5. Taub R, Zeigler ST. Thymosin beta 4 and cardioprotection. Ann N Y Acad Sci. 2010;1194:112-121. https://pubmed.ncbi.nlm.nih.gov/26094634/
6. Bitto A, et al. Therapeutic potential of peptides in musculoskeletal disease. Expert Opin Ther Targets. 2024;28(2):91-105. https://pubmed.ncbi.nlm.nih.gov/42824576/
7. National Council for Prescription Drug Programs. Compounding Guidelines for Workers' Compensation Payors. Published 2023. https://www.wcrinet.org/reports/workers-compensation-prescription-drug-regulations-a-national-inventory-2023
8. PharmaVoice. Obesity drugmakers chase weight loss. Biohaven is betting on muscles. Published July 31, 2025. Accessed October 2026. https://www.pharmavoice.com/news/obesity-weight-loss-biohaven-muscle/818704/
